{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:15:01Z","timestamp":1790000101793,"version":"4.0.1"},"reference-count":91,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Association of Dermatologists from Moldova"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Differentiating psoriasis from psoriasiform dermatitis can be challenging due to overlapping clinical and morphological features, especially in certain areas, such as the palms, soles and scalp. While the distinct roles of the Th17 and Th2 axes in these inflammatory dermatoses are recognized, the comprehensive in situ expression of adhesion molecules, inflammatory cytokines, and structural markers within a unified diagnostic framework remains incompletely characterized. Objectives: The aim of this study was to compare the immunohistochemical expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), tumor necrosis factor-alpha (TNF-\u03b1), interleukin-1 beta (IL-1\u03b2), interleukin-17A (IL-17A), Collagen IV, and S100B in psoriasis and psoriasiform dermatitis and to evaluate their diagnostic and pathogenetic significance. Methods: This retrospective observational study evaluated skin biopsy specimens from 22 patients: 11 with psoriasis and 11 with psoriasiform dermatitis. Immunohistochemical staining was performed for seven markers. Expression intensity was semi-quantitatively scored (0\u20133) across four compartments: membranous, cytoplasmic, nuclear, and inflammatory infiltrate. Statistical analysis included Mann\u2013Whitney U tests with effect size calculations and receiver operating characteristic (ROC) analysis with bootstrap confidence intervals. Results: Psoriasis lesions demonstrated significantly higher total expression scores compared with psoriasiform dermatitis for IL-17A (median 8 vs. 4, p &lt; 0.001, r = 0.847), IL-1\u03b2 (8 vs. 4, p &lt; 0.001, r = 0.847), TNF-\u03b1 (8 vs. 4, p &lt; 0.001, r = 0.819), and ICAM-1 (9 vs. 4, p = 0.003, r = 0.637). VCAM-1 showed a higher median expression score in psoriasis (7 vs. 6), but the difference was not statistically significant (p = 0.134, r = 0.322). Structural markers Collagen IV (p = 0.110) and S100B (p = 0.504) showed no significant differences. ROC analysis yielded an AUC of 1.000 for both IL-17A and IL-1\u03b2, followed by TNF-\u03b1 (AUC = 0.983) and ICAM-1 (AUC = 0.876). VCAM-1 exhibited moderate discriminative ability (AUC = 0.694). A combined biomarker panel (IL-17A, TNF-\u03b1, and ICAM-1) achieved an AUC of 1.000 within this study cohort; however, this exploratory finding requires external validation. Conclusions: IL-17A, IL-1\u03b2, TNF-\u03b1, and ICAM-1 represent the most discriminative immunohistochemical markers separating psoriasis from psoriasiform dermatitis. In this preliminary study, IL-17A, IL-1\u03b2, TNF-\u03b1, and ICAM-1 showed the greatest between-group differences and the highest diagnostic performance within the investigated cohort. VCAM-1 may provide complementary diagnostic information. Collagen IV and S100B appear less useful as standalone discriminators. These findings support the potential role of biomarker-guided precision dermatopathology, although validation in larger independent cohorts is required before clinical implementation.<\/jats:p>","DOI":"10.3390\/diagnostics16183047","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:03Z","timestamp":1789995003000},"page":"3047","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Immunoprofiling in Psoriasis and Psoriasiform Dermatitis Using Inflammatory and Structural Biomarkers: A Preliminary Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-836X","authenticated-orcid":false,"given":"Mihaela Paula","family":"Toader","sequence":"first","affiliation":[{"name":"Department of Surgicals, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Pathology Laboratory, University Clinical Railways Hospital, 700506 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Oana Mihaela Condurache","family":"Hritcu","sequence":"additional","affiliation":[{"name":"Department of Surgicals, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"given":"Mirela","family":"Grigorovici","sequence":"additional","affiliation":[{"name":"Pathology Laboratory, University Clinical Railways Hospital, 700506 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Stefan","family":"Toader","sequence":"additional","affiliation":[{"name":"Department of Surgicals, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-0296","authenticated-orcid":false,"given":"Carmen","family":"Solcan","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Histology and Embryology, University of Life Sciences Ion Ionescu de la Brad, 700489 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Daciana Elena","family":"Branisteanu","sequence":"additional","affiliation":[{"name":"Department of Surgicals, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Pathology Laboratory, University Clinical Railways Hospital, 700506 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref_5","first-page":"2546","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"135","author":"Noda","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, M., Wang, J., Liu, Q., Liu, Y., Mi, W., Li, W., and Li, J. (2025). Beyond the dichotomy: Understanding the overlap between atopic dermatitis and psoriasis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1541776"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.2147\/CCID.S574980","article-title":"Immunological Antagonism Between Psoriasis and Atopic Dermatitis: Pathways, Clinical Implications, and Therapeutic Perspectives","volume":"18","author":"Qin","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum?","volume":"48","author":"Krueger","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5021\/ad.2016.28.4.427","article-title":"Histopathological Differential Diagnosis of Psoriasis and Seborrheic Dermatitis of the Scalp","volume":"28","author":"Park","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Nestle","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014Part II: Immune cell subsets and therapeutic concepts","volume":"127","author":"Nograles","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: The leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/349796a0","article-title":"ELAM-1 is an adhesion molecule for skin-homing T cells","volume":"349","author":"Picker","year":"1991","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/archderm.1989.01670220102017","article-title":"Mechanisms of cutaneous inflammation: Interactions between epidermal cytokines, adhesion molecules, and leukocytes","volume":"125","author":"Kupper","year":"1989","journal-title":"Arch. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2133.2007.08039.x","article-title":"Adhesion of patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1","volume":"157","author":"Watabe","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0092-8674(89)90775-7","article-title":"Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes","volume":"59","author":"Osborn","year":"1989","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Marinovi\u0107 Kuli\u0161i\u0107, S., Takahashi, M., Himelreich Peri\u0107, M., Mu\u017ei\u0107 Radovi\u0107, V., and Juraki\u0107 Ton\u010di\u0107, R. (2023). Immunohistochemical Analysis of Adhesion Molecules E-Selectin, Intercellular Adhesion Molecule-1, and Vascular Cell Adhesion Molecule-1 in Inflammatory Lesions of Atopic Dermatitis. Life, 13.","DOI":"10.3390\/life13040933"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-0960.1994.tb00898.x","article-title":"Endothelial cell adhesion molecules in psoriasis","volume":"35","author":"Lee","year":"1994","journal-title":"Australas. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archderm.1994.01690040098016","article-title":"Cutaneous leukocyte trafficking and psoriasis","volume":"130","author":"Griffiths","year":"1994","journal-title":"Arch. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","first-page":"15","article-title":"Epidermal signaling in inflammatory skin diseases","volume":"90","author":"Buerger","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Macho\u0144, N.J., Zdanowska, N., Klimek-Trojan, P., and Owczarczyk-Saczonek, A. (2025). Vascular Cell Adhesion Molecule 1 and E-Selectin as Potential Cardiovascular Risk Biomarkers in Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020792"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ng.313","article-title":"Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis","volume":"41","author":"Zeeuwen","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"Huffmeier","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Capon, F. (2017). The Genetic Basis of Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122526"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/jid.2009.319","article-title":"Molecular dissection of psoriasis: Integrating genetics and biology","volume":"130","author":"Elder","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anai.2023.09.009","article-title":"Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives","volume":"132","author":"Stefanovic","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/jid.2011.393","article-title":"One remarkable molecule: Filaggrin","volume":"132","author":"Brown","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","first-page":"265","article-title":"Mechanisms of abnormal percutaneous assimilation in atopic dermatitis","volume":"41","author":"Elias","year":"2011","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ng.2642","article-title":"High-density genotyping study identifies four new susceptibility loci for atopic dermatitis","volume":"45","author":"Ellinghaus","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1093\/hmg\/ddt317","article-title":"A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis","volume":"22","author":"Weidinger","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin mutations associated with skin and allergic diseases","volume":"365","author":"Irvine","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ng.3424","article-title":"Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis","volume":"47","author":"Paternoster","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2340\/00015555-2200","article-title":"Are common skin diseases among Norwegian dermatology outpatients associated with psychological problems compared with controls? An observational study","volume":"96","author":"Balieva","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic burden of psoriasis in the United States: A systematic review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: Global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann. Nutr. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: Psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/bmj.299.6710.1259","article-title":"Hay fever, hygiene, and household size","volume":"299","author":"Strachan","year":"1989","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.19723","article-title":"Atopic dermatitis: A global health perspective","volume":"38","author":"Faye","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, H.J., and Kim, M. (2023). Challenges and future trends for atopic dermatitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411380"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2006.02.006","article-title":"Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus","volume":"24","author":"Howell","year":"2006","journal-title":"Immunity"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12788\/j.sder.2017.036","article-title":"Atopic dermatitis: Pathogenesis","volume":"36","author":"Waldman","year":"2017","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/1346-8138.15664","article-title":"Basics and recent advances in the pathophysiology of atopic dermatitis","volume":"48","author":"Nakahara","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_68","first-page":"992","article-title":"Abnormal epidermal barrier recovery in uninvolved psoriatic skin","volume":"171","author":"Ye","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kabashima, K., and Irie, H. (2021). Interleukin-31 as a Clinical Target for Pruritus Treatment. Front. Med., 8.","DOI":"10.3389\/fmed.2021.638325"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Simpson","year":"2016","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK Inhibitors for Atopic Dermatitis: An Update","volume":"20","author":"He","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Pangan","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: A multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Simpson","year":"2023","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaci.2021.10.022","article-title":"Advances in atopic dermatitis in 2019\u20132020: Endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells","volume":"148","author":"Nomura","year":"2021","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/18\/3047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:22:35Z","timestamp":1789996955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/18\/3047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":91,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diagnostics16183047"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16183047","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}